Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy

Current Therapeutic Research - Clinical and Experimental

Volumn 74, Issue , 2013, Pages 62-67

  Ono, Takashi ^a,b   Sanai, Toru ^c   Miyahara, Yoshito ^a   Noda, Ritsuya ^a  

^a SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^b Renal Division   (Japan)

^c Fukumitsu Hospital   (Japan)

Author keywords

Angiotensin II receptor antagonist; Nondiabetic chronic kidney disease; Olmesartan; Proteinuria

Indexed keywords

CANDESARTAN; CREATININE; LOSARTAN; OLMESARTAN; POTASSIUM; PROTEIN; VALSARTAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MEDICAL RECORD REVIEW; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 84879430990     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.02.002     Document Type: Article

References (25)

1. Deferrari G., Ravera M., Deferrari L., et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol 2002, 13(Suppl 3):S224-S229.
2. Brenner B.M., Cooper M.E., Zeeuw D., et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
3. Nakai S, Suzuki K, Masakane I, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial. 2010;14:505-540.
4. Imai E., Horio M., Nitta K., et al. Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007, 50:927-937.
5. Imai E., Horio M., Iseki K., et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007, 11:156-163.
6. Toto R.D. Treatment of hypertension in chronic kidney disease. Semin Nephrol 2005, 25:435-439.
7. Lewis E.J., Hunsicker L.G., Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Kidney Int 2001, 345:851-860.
8. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
9. Geng R.W., Liu Z.R., Wang G.B., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
10. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16:3038-3045.
11. Sharma P., Blackburm R.C., Parke C.L., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev 2011, 10:7751.
12. Jang H.R., Lee Y.J., Kim S.G., et al. Potential role of urinary angiotensinogen in predicting antiproteinuric effects of angiotensin receptor blocker in non-diabetic chronic kidney disease patients: a preliminary report. Postgrad Med J 2012, 1038:210-216.
13. Katayama K., Nomura S., Ishikawa H., et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006, 70:151-156.
14. Wang L., Zhao J.W., Liu B., et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am J Cardiovasc Drugs 2012, 5:335-344.
15. Punzi H.A., Lewin A., Li W., et al. Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. Adv Ther 2012, 6:524-537.
16. Oparil S., Williams D., Chrysant S.G., et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2002, 3:283-291.
17. Smith D.H., Dubiel R., Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005, 5:41-50.
18. Miura S., Fujino M., Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005, 1:115-121.
19. Tsutamoto T., Nishiyama K., Yamaji M., et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010, 33:118-122.
20. Iwai M., Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hyertens Res 2009, 7:533-536.
21. Levi B.I. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005, 18:134-141.
22. Ichikawa S., Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001, 24:641-646.
23. Kaiqiang J., Minakawa M., Fukui K., et al. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther Adv Cardiovasc Dis 2009, 3:103-111.
24. Agata J., Ura N., Yoshida H., et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006, 29:865-874.
25. Igase M, Kohara K. Nagai T, et al. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 2008;31:553-559.